2seventy bio (TSVT) Stock Price, News & Analysis

Company Overview

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $4.95 to $4.96
• 50-Day Range: $2.30 to $4.96
• 52-Week Range: $2.29 to $5.99
• Volume: 512,434 shs
• Average Volume: 602,846 shs
• Market Capitalization: $255.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.67
• Consensus Rating: Hold

2seventy bio Stock Analysis - MarketRank™

2seventy bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 415th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

2seventy bio has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 2 buy ratings, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

2seventy bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 2seventy bio are expected to grow in the coming year, from ($1.46) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 2seventy bio is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 2seventy bio is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

2seventy bio has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.18% of the float of 2seventy bio has been sold short.

Short Interest Ratio / Days to Cover

2seventy bio has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in 2seventy bio has recently decreased by 6.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

2seventy bio does not currently pay a dividend.

Dividend Growth

2seventy bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.18% of the float of 2seventy bio has been sold short.

Short Interest Ratio / Days to Cover

2seventy bio has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in 2seventy bio has recently decreased by 6.61%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.50

News Sentiment

2seventy bio has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for 2seventy bio this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for TSVT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 2seventy bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,400,018.00 in company stock.

Percentage Held by Insiders

Only 7.20% of the stock of 2seventy bio is held by insiders.

Percentage Held by Institutions

93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TSVT Stock Analysis - Frequently Asked Questions

How have TSVT shares performed this year?

2seventy bio's stock was trading at $2.94 at the start of the year. Since then, TSVT stock has increased by 68.4% and is now trading at $4.95.
View the best growth stocks for 2025 here.

How were 2seventy bio's earnings last quarter?

2seventy bio, Inc. (NASDAQ:TSVT) announced its earnings results on Tuesday, March, 5th. The company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.22) by $0.11. The company earned $10.68 million during the quarter, compared to analysts' expectations of $13.91 million. 2seventy bio had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 207.25%.

Who are 2seventy bio's major shareholders?

Top institutional shareholders of 2seventy bio include Newtyn Management LLC (4.91%), Bank of America Corp DE (4.88%), Regeneron Pharmaceuticals Inc. (2.43%) and Eversept Partners LP (1.95%). Insiders that own company stock include Kynam Capital Management, Lp, Casdin Capital, Llc, William D Baird III, Nick Leschly, Victoria Eatwell, Jessica Snow, Philip D Gregory, Nicola Heffron, Marcela V Maus and Global Healthcare Master Kynam.
View institutional ownership trends.

How do I buy shares of 2seventy bio?

Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 2seventy bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 3/05/2024
• Today: 3/26/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TSVT
• CIK: 1860782
• Web: www.2seventybio.com
• Phone: 339-499-9300
• Fax: N/A
• Employees: 440
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.67
• High Stock Price Target: $12.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +34.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.38
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-217,570,000.00
• Net Margins: -207.25%
• Pretax Margin: -207.25%
• Return on Equity: -53.65%
• Return on Assets: -23.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.95
• Quick Ratio: 4.95

Sales & Book Value

• Annual Sales: $45.62 million
• Price / Sales: 5.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.04 per share
• Price / Book: 0.98

Miscellaneous

• Outstanding Shares: 51,588,000
• Free Float: 47,874,000
• Market Cap: $255.36 million
• Optionable: Optionable
• Beta: 1.73